• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019年加拿大的处方药支出:聚焦公共药品计划

Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs.

作者信息

Lee Kathy, Jani Trupti, Cheng Roger, Hunt Jordan

机构信息

A program lead in the Pharmaceuticals Department at the CIHI in Ottawa, Ontario. She leads and coordinates the analysis and writing of pharmaceutical-related reports at CIHI. Kathy can be reached at

A senior analyst in the Pharmaceuticals Department at the CIHI in Ottawa, Ontario. She assisted with the analysis and writing of the Drug Spending in Canada reports at CIHI. Trupti can be reached at

出版信息

Healthc Q. 2020 Apr;23(1):10-12. doi: 10.12927/hcq.2020.26145.

DOI:10.12927/hcq.2020.26145
PMID:32249733
Abstract

Public drug program spending accounts for 43.1% of prescribed drug spending in Canada. This report provides an in-depth look at public drug program spending in Canada, using the Canadian Institute for Health Information's (CIHI) National Prescription Drug Utilization Information System. Public drug program spending does not include spending on drugs dispensed in hospitals or on those funded through cancer agencies and other special programs.

摘要

公共药品项目支出占加拿大处方药支出的43.1%。本报告利用加拿大卫生信息研究所(CIHI)的全国处方药利用信息系统,深入探讨了加拿大公共药品项目的支出情况。公共药品项目支出不包括医院配药支出或通过癌症机构及其他特殊项目资助的药品支出。

相似文献

1
Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs.2019年加拿大的处方药支出:聚焦公共药品计划
Healthc Q. 2020 Apr;23(1):10-12. doi: 10.12927/hcq.2020.26145.
2
Refining estimates of public health spending as measured in national health expenditure accounts: the Canadian experience.在国民卫生支出账户中衡量公共卫生支出的精细化估计:加拿大的经验。
J Public Health Manag Pract. 2007 Mar-Apr;13(2):115-20. doi: 10.1097/00124784-200703000-00006.
3
National trends in prescription drug expenditures and projections for 2019.全国处方药支出趋势及 2019 年预测。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1105-1121. doi: 10.1093/ajhp/zxz109.
4
Trends in Prescription Drug Spending Leading Up to Health Reform.医疗改革前处方药支出的趋势。
Med Care Res Rev. 2014 Aug;71(4):416-32. doi: 10.1177/1077558714533820. Epub 2014 May 14.
5
Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?全球处方药支付情况:为何美国与众不同?
Issue Brief (Commonw Fund). 2017 Oct 1;2017:1-14.
6
Drug costs surpass spending on physicians.药品成本超过了医生的支出。
CMAJ. 2000 Feb 8;162(3):405.
7
Trends in out-of-pocket health care expenditures in Canada, by household income, 1997 to 2009.加拿大 1997 年至 2009 年按家庭收入划分的自付医疗保健支出趋势。
Health Rep. 2014 Apr;25(4):13-7.
8
Recommendations for Lowering Prescription Drug Spending in Public Programs.降低公共项目中处方药支出的建议。
Ann Intern Med. 2019 Dec 3;171(11):855-856. doi: 10.7326/M19-2895. Epub 2019 Nov 12.
9
Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.9 个加拿大省份公共药物计划中高药费受益人的特征:一项横断面分析。
CMAJ Open. 2020 Apr 28;8(2):E297-E303. doi: 10.9778/cmajo.20190231. Print 2020 Apr-Jun.
10
New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US.治疗丙型肝炎的新药致使美国处方药支出增长了13%。
BMJ. 2015 Apr 17;350:h2055. doi: 10.1136/bmj.h2055.

引用本文的文献

1
The impact of prescription drug insurance on cost related non-adherence to medications in Canada: A Heckman sample selection approach.加拿大处方药保险对与费用相关的药物不依从性的影响:Heckman 样本选择方法。
PLoS One. 2023 Aug 9;18(8):e0289776. doi: 10.1371/journal.pone.0289776. eCollection 2023.
2
Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study.直接口服抗凝剂-质子泵抑制剂联合治疗与不良结局的关联:一项基于人群的队列研究方案。
BMJ Open. 2022 Jun 13;12(6):e057991. doi: 10.1136/bmjopen-2021-057991.
3
Trends in Canadian prescription drug purchasing: 2001-2020.
2001 - 2020年加拿大处方药购买趋势
J Pharm Policy Pract. 2022 Mar 17;15(1):20. doi: 10.1186/s40545-022-00420-4.
4
Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study.不列颠哥伦比亚省炎性关节炎和银屑病患者中,英夫利昔单抗由原研药转为生物类似药的强制性非医学转换:一项队列研究。
CMAJ Open. 2022 Feb 15;10(1):E109-E118. doi: 10.9778/cmajo.20200319. Print 2022 Jan-Mar.
5
Community pharmacists' evolving role in Canadian primary health care: a vision of harmonization in a patchwork system.社区药剂师在加拿大初级卫生保健中不断演变的角色:拼凑系统中的协调愿景。
Pharm Pract (Granada). 2020 Oct-Dec;18(4):2171. doi: 10.18549/PharmPract.2020.4.2171. Epub 2020 Oct 18.
6
Biosimilars versus biologics for inflammatory conditions.用于炎症性疾病的生物类似药与生物制品对比
Can Fam Physician. 2019 Sep;65(9):636.